Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)
Robyn M. Scherber(Blueprint Medicines (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Jean‐Jacques Kiladjian(Délégation Paris 5), Francesco Passamonti(University of Milan), Frank Stegelmann(University Hospital Ulm), Pablo Muxí(Hospital Británico), Gunnar Birgegård(Uppsala University Hospital), Jean‐Christophe Ianotto(Inserm), Xiujuan Sun(Chinese Academy of Sciences), Heike L. Pahl(University Medical Center Freiburg), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Carlos Besses(Hospital Del Mar), Dolores Hernández‐Maraver(Centre Hospitalier Universitaire de Grenoble), Andreas Reiter(Heidelberg University), Thomas Lehmann(University of Basel), Deepti Radia(St Thomas' Hospital), Maria Luisa Ferrari(University of Bergamo), Harry C. Schouten, Heidi Kosiorek(Mayo Clinic in Florida), Jean‐Yves Cahn, Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Jan Samuelsson(Karolinska University Hospital), Peter Johansson(Linköping University), Konstanze Döhner(University Hospital Ulm), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Federico Sackmann(Centre Hospitalier Universitaire de Grenoble), Holly L. Geyer(Mayo Clinic Hospital), Zhijian Xiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Stefanie Slot(Amsterdam UMC Location Vrije Universiteit Amsterdam), Tiziano Barbui(University of Bergamo), Gabriel Étienne(Institut Bergonié), Karin Bonatz(Centre Hospitalier Universitaire de Grenoble), Suzan Commandeur(Leiden University), Dana Ranta(Centre Hospitalier Régional et Universitaire de Nancy), Sonja Zweegman(Vrije Universiteit Amsterdam), Robert Peter Gale(Imperial College London), Giovanni Barosi(Policlinico San Matteo Fondazione), Amylou C. Dueck(Mayo Clinic in Arizona), Junqing Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Zefeng Xu(Henan University), Peihong Zhang(Tongji University), Yu Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Norman I Maldonado(University of Puerto Rico System), Françoise Boyer(Centre Hospitalier Universitaire d'Angers), Peter A. te Boekhorst(Erasmus MC), Jean Roy(Hôpital Maisonneuve-Rosemont), Ana Kerguelen Fuentes(Centre Hospitalier Universitaire de Grenoble), Martin Grießhammer(Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie)
Cited by 5
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k